Press Releases Ypsomed Group

Burgdorf - The guidance of CHF 60 million EBIT for the 2017/18 financial year announced in November 2017 remains unchanged. Ypsomed is investing in its global expansion and the establishment of new subsidiaries for the insulin pump business. Ypsomed expects sustained growth in the Ypsomed Delivery Systems (YDS) segment.

Swisscom and Ypsomed test 5G in production operations for the first time

Press Releases Ypsomed Group

Burgdorf - Swisscom and Ypsomed have been cooperating since the spring of 2017 to develop application options for the latest generation of mobile communications. Ypsomed has digitised selected production processes with 5G. This simplifies processes considerably, makes them even safer and more efficient.

Ypsomed is driving the digitisation of its portfolio

Press Releases Ypsomed Group

Burgdorf – Ypsomed continues to expand its offers for digital diabetes therapy with the launch of the mylife™ App. The mylife™ App is connected to the mylife™ YpsoPump® insulin pump via Bluetooth® and continuously records current therapy data. Digital therapy solutions add to customer benefit and increase the success of therapy long-term.

Press Releases Ypsomed Group

Burgdorf - During the first six months of the business year 2017/18, Ypsomed generated a consolidated total turnover of CHF 213.4 million. The growth corresponds to an increase in turnover of 15.1% (previous year: CHF 185.4 million). The net profit for the reporting period amounts to CHF 23.4 million (previous year CHF 22.4 million). The operating result amounts to CHF 26.9 million with an EBIT margin of 12.9 %. Ypsomed expects a growth in turnover of approximately 18% versus the presently forecast 15% and increases the forecast to an operating result of around CHF 60 million for the business year 2017/18.

Press Releases Ypsomed Group

Burgdorf – Ypsomed and the US Bigfoot Biomedical company today announced their agreement for a partnership. Ypsomed will supply Bigfoot Biomedical with a modified, patented version of the Orbit infusion set. This will be used by Bigfoot in their clinical study on automated insulin therapy in people with diabetes.